Cleanroom Technologies Market Size, Share | MarketsandMarkets

The growth of this market is majorly driven by the stringent regulatory framework, growth of the biologics sector, rising demand for parenteral and injectable pharmaceutical formulations, growing demand for medical devices, and advancements in cleanroom technologies. However, the high operational costs associated with cleanrooms is expected to restrain the growth of this market during the forecast period.

Browse and in-depth TOC on “Cleanroom Technologies Market”
289 — Tables
41 — Figures
313 — Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263122482

Key Findings of the Study:

1. The consumables segment is expected to grow at the highest CAGR during the forecast period.
2. The standard/drywall cleanrooms segment accounted for the largest share of the cleanroom technologies market.
3. Biotechnology is expected to grow at the highest rate during the forecast period.
4. North America is expected to hold the largest share for players operating in the cleanroom technologies market.

List of Key Players:

The prominent players in the global cleanroom technologies market are Azbil Corporation (Japan), Kimberly-Clark Corporation (US), Ardmac (Ireland), Clean Air Products (US), Labconco Corporation (US), Dynarex Corporation (US), DuPont de Nemours, Inc. (US), Illinois Tool Works, Inc. (US), Taikisha Ltd. (Japan), Exyte AG (Germany), COLANDIS GmbH (Germany), ABN Cleanroom Technology (Belgium), Clean Rooms International, Inc. (US), and, Bouygues Group (France).

The biotechnology industry is one of the major contributors to the growth of the global life science industry. In the past few years, the healthcare industry has seen the emergence of several biologic molecules. Moreover, new drug development research is highly focused on biological products. Over the last decade, over 200 biologics have been approved by the US FDA. The biopharmaceutical industry has witnessed the emergence of a new class of therapeutics showing significant potential in new treatments in oncology, diabetes, and other disease areas. Currently, there are hundreds of monoclonal antibodies, vaccines, and biologics in clinical development. The faster approval of new drugs drives the demand for cleanrooms for their manufacturing. Also, since many of the biologics are pathogenic, it is essential to maintain aseptic conditions during their manufacturing. Thus, cleanrooms form an essential component in the manufacturing of biologics.